JP Morgan made a bold call on MRNA Thursday. Analyst Jessica Fye nearly doubled her price target — from $40 to $77. She kept a Sell rating. That gap between a bullish target and a bearish rating signals a complex view on the biotech's recovery path. Moderna carries 13.3% short interest as a percentage of free float, suggesting many investors remain sceptical.
In retail, JP Morgan's Matthew Boss upgraded ROST to Buy and lifted his target from $262 to $272. Ross Stores is a $73B off-price retailer. Short interest sits at just 3%, so there's little short-side resistance. Boss may be betting on trade deal tailwinds helping discount chains.
NWSA also caught a JP Morgan upgrade. David Karnovsky raised his target from $36 to $38 and moved to Buy. News Corp's $10.7B market cap makes this a mid-cap call worth watching.
Utilities pulled back. Morgan Stanley cut targets on EXC and ETR, citing valuation. FE saw a target trim too, despite keeping a Buy rating. The three cuts paint a cautious picture for the regulated utility space heading into autumn.
DE got a consensus target lift to $659, reflecting steady demand for agricultural equipment.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
